Virology
Lamivudine does not clear hepatitis D virus infection
Published in Hepatitis Weekly, September 26th, 2005
"Delta virus (HDV)-related chronic hepatitis is difficult to treat," scientists in Italy report.
G.A. Niro and colleagues, Casa Sollievo della Sofferenza Hospital conducted research "to evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion."
"Thirty-one hepatitis B surface antigen-positive, HDV-RNA-positive patients with ALT {{>=}}1.5 upper normal level and compensated liver disease were randomized (1:2 ratio) to placebo (group A,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-09-26)
More Articles from Hepatitis Weekly
- Allergy & Immunology
Fas ligand from T cells may ignite hepatitis C-related liver inflammation - Diagnostics
DNA genosensor seeks evidence of lamivudine-resistant hepatitis B - Hepatitis B Virus
Hepatitis B vaccine response fails in liver graft patients receiving lamivudine - Hepatitis C Therapy
Extended ribavirin after combination therapy leaves hepatitis C unchecked - Oncology
Hepatitis B virus DNA may trigger cancer after hepatitis C virus clearance - Adverse Drug Reaction
Alosetron may trigger liver injury in patients with irritable bowel syndrome - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
